Wilmington, DE – Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients (APIs), and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and the development and licensing of unique dosage forms, have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers of finished dosage forms.
The agreement will focus on finished dosage products for licensing to customers through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies. Neither Noramco nor SPI has any intention to produce or market finished dosage forms.
“Bringing together Noramco’s expertise in API production with SPI Pharma’s know-how in formulation development and technology transfer allows us to create compliant, novel dosage forms, ready-to-implement at a site of our customers’ choosing,” said Bill Grubb, Vice President of Global Strategy and Innovation, Noramco.
SPI Pharma’s Chief Scientific Officer, Sarath Chandar, said, “We expect to create a winning formula for pharma customers worldwide through the combination of SPI’s strong track record of developing and licensing successful 505b(2) type drug packages featuring our patented platforms and Noramco’s proprietary API technologies.”
Noramco and SPI Pharma will demonstrate proof-of-concept (POC) of a select set of finished drug products in patient-friendly dosage forms, which will be out-licensed to customers for scale-up, registration, and marketing. Customers can also choose upfront to customize formulation packages for specific APIs on a milestone-based, pay-for-success business model.
“Pharmaceutical companies that normally purchase APIs from Noramco but have an additional need for speed-to-market, a reduction in trial-and-error, product differentiation, life-cycle management, and technical/regulatory support may now call on us for comprehensive formulation packages,” Grubb said.
For further information, visit www.spipharma.com and www.noramco.com.
Noramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. The company offers cannabinoids and APIs for use in abuse deterrence, attention deficit disorder, pain management, and addiction management. Established in 1979, Noramco maintains production and R&D facilities in Delaware and Georgia (USA); and Neuhausen, Switzerland; and accesses agricultural operations in Tasmania through an affiliate, Tasmanian Alkaloids. Additional information about us can be obtained by visiting our web site at www.Noramco.com
About SPI Pharma
SPI Pharma, headquartered in Wilmington, Delaware, provides innovative solutions to global pharmaceutical and nutritional customers. Product lines include Antacid Actives, Excipients, Drug Delivery Systems, Taste-Masking, and Vaccine Adjuvants. SPI Pharma specializes in drug development services, having participated in over 60 commercially launched and marketed drugs globally. Leveraging the backing of its parent company, Associated British Foods plc, and its sites in the US, France and India, the company solves the most challenging formulation problems- efficiently, cost-effectively, and with a focus on service. For further information on SPI, please visit www.spipharma.com
Vice President, Business Development
SPI Pharma Contact
Global Business Development Manager